parallel randomized trial
S003437
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Metformin Diacerein plus metformin 1000 mg per day | diacerein 50 to 100 mg per day and nonpharmacological recommendations; lifestyle: standard | 60 | ||
| A2 | Semaglutide 1.0 mg subcutaneous once weekly Diacerein plus semaglutide up to 1.0 mg | diacerein 50 to 100 mg/day and nonpharmacological recommendations; lifestyle: standard | 60 | ||
| A3 | Semaglutide 2.4 mg subcutaneous once weekly Diacerein plus semaglutide up to 2.4 mg | diacerein 50 to 100 mg/day and nonpharmacological recommendations; lifestyle: standard | 60 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Metformin A1 | Semaglutide 1.0 mg subcutaneous once weekly A2 | Semaglutide 2.4 mg subcutaneous once weekly A3 | Whole trial ALL |
|---|---|---|---|---|---|
| hba1c | mean (percent) | 7.84 | |||
| weight | mean (kg) | 99.1 | 99.2 |
Analyses this trial contributes to
- Level 2 or 3 hypoglycemia (participants)Type 2 diabetes (adults); longest follow-up; network meta-analysis
- Level 2 or 3 hypoglycemia (participants)Type 2 diabetes (adults); longest follow-up; network meta-analysis
- Serious adverse eventsType 2 diabetes (adults); longest follow-up; network meta-analysis
- Serious adverse eventsType 2 diabetes (adults); longest follow-up; network meta-analysis
- Serious adverse eventsKnee osteoarthritis; longest follow-up; descriptive only
- Serious adverse eventsKnee osteoarthritis; longest follow-up; descriptive only
- Acute pancreatitisKnee osteoarthritis; longest follow-up; descriptive only
- Acute pancreatitisKnee osteoarthritis; longest follow-up; descriptive only
- Acute pancreatitisType 2 diabetes (adults); longest follow-up; network meta-analysis
- Acute pancreatitisType 2 diabetes (adults); longest follow-up; network meta-analysis
Results
13 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Body weight change in kilograms (diabetes) (2 lines; O02)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 26.07 | A2 | final | 92.4 kg | not stated; other; R0053478:Results | |||
| 26.07 | A3 | final | 91.1 kg | not stated; other; R0053478:Results |
Level 2 or 3 hypoglycemia (participants) (3 lines; O04)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 60 | not stated; randomized; R0053478:Results | ||||
| A2 | events | 0 / 60 | not stated; randomized; R0053478:Results | ||||
| A3 | events | 0 / 60 | not stated; randomized; R0053478:Results |
Percent body weight change (2 lines; O10)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 26.07 | A2 | percent change | -6.82 percent | not stated; other; R0053478:Results | |||
| 26.07 | A3 | percent change | -8.20 percent | not stated; other; R0053478:Results |
Serious adverse events (3 lines; O25)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 60 | not stated; randomized; R0053478:Results | ||||
| A2 | events | 0 / 60 | not stated; randomized; R0053478:Results | ||||
| A3 | events | 0 / 60 | not stated; randomized; R0053478:Results |
Acute pancreatitis (3 lines; O29)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 60 | not stated; randomized; R0053478:Results | ||||
| A2 | events | 0 / 60 | not stated; randomized; R0053478:Results | ||||
| A3 | events | 0 / 60 | not stated; randomized; R0053478:Results |